Wall Street analysts expect that Alcobra Ltd (NASDAQ:ADHD) will announce ($0.20) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Alcobra’s earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.25). Alcobra reported earnings per share of ($0.18) during the same quarter last year, which would indicate a negative year over year growth rate of 11.1%. The company is scheduled to issue its next quarterly earnings report on Monday, May 15th.
On average, analysts expect that Alcobra will report full-year earnings of ($0.71) per share for the current fiscal year, with EPS estimates ranging from ($0.81) to ($0.61). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.48) per share, with EPS estimates ranging from ($0.61) to ($0.35). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Alcobra.
Alcobra (NASDAQ:ADHD) last released its earnings results on Wednesday, February 15th. The biotechnology company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.04.
A number of brokerages have weighed in on ADHD. Zacks Investment Research lowered shares of Alcobra from a “buy” rating to a “hold” rating in a research report on Tuesday. Cantor Fitzgerald restated a “hold” rating and issued a $1.00 target price on shares of Alcobra in a research report on Thursday, April 13th. Jefferies Group LLC restated a “hold” rating and issued a $1.25 target price on shares of Alcobra in a research report on Friday, March 31st. Finally, Roth Capital upgraded shares of Alcobra from a “neutral” rating to a “buy” rating and set a $4.00 target price on the stock in a research report on Thursday, February 9th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the stock. Alcobra has an average rating of “Hold” and a consensus target price of $1.93.
TRADEMARK VIOLATION WARNING: “Alcobra Ltd (ADHD) Expected to Announce Earnings of -$0.20 Per Share” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/2486087/alcobra-ltd-adhd-expected-to-announce-earnings-of-0-20-per-share.html.
Alcobra (NASDAQ:ADHD) traded down 3.51% during midday trading on Tuesday, reaching $1.10. The company had a trading volume of 241,960 shares. The stock’s 50 day moving average price is $1.16 and its 200-day moving average price is $1.67. The firm’s market capitalization is $30.32 million. Alcobra has a one year low of $0.83 and a one year high of $5.75.
A number of hedge funds have recently modified their holdings of ADHD. J. Goldman & Co LP bought a new stake in shares of Alcobra during the fourth quarter worth $546,000. Royce & Associates LP increased its position in Alcobra by 367.2% in the fourth quarter. Royce & Associates LP now owns 645,055 shares of the biotechnology company’s stock valued at $1,355,000 after buying an additional 507,000 shares during the last quarter. Kingdon Capital Management L.L.C. increased its position in Alcobra by 63.8% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 650,000 shares of the biotechnology company’s stock valued at $1,365,000 after buying an additional 253,200 shares during the last quarter. VHCP Management LLC increased its position in Alcobra by 5.7% in the third quarter. VHCP Management LLC now owns 658,910 shares of the biotechnology company’s stock valued at $1,628,000 after buying an additional 35,597 shares during the last quarter. Finally, Knoll Capital Management LP acquired a new position in Alcobra during the third quarter valued at about $2,799,000. Hedge funds and other institutional investors own 63.20% of the company’s stock.
Alcobra Company Profile
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alcobra Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd and related companies with MarketBeat.com's FREE daily email newsletter.